Literature DB >> 29542187

Multiplex PCR in noninvasive prenatal diagnosis for FGFR3-related disorders.

Sumire Terasawa1,2, Asuka Kato1, Haruki Nishizawa1, Takema Kato2, Hikari Yoshizawa1,2, Yoshiteru Noda1,2, Jun Miyazaki1,2, Mayuko Ito1,2, Takao Sekiya1, Takuma Fujii1, Hiroki Kurahashi2.   

Abstract

Thanatophoric dysplasia and achondroplasia are allelic disorders caused by a constitutively active mutation in the FGFR3 gene. Because thanatophoric dysplasia is a lethal disorder and achondroplasia is non-lethal, they need to be distinguished after ultrasound identification of fetal growth retardation with short limbs. Accordingly, we have developed a noninvasive prenatal test using cell-free fetal DNA in the maternal circulation to distinguish thanatophoric dysplasia and achondroplasia. A multiplex PCR system encompassing five mutation hotspots in the FGFR3 gene allowed us to efficiently identify the responsible mutation in cell-free DNA in all examined pregnancies with a suspected thanatophoric dysplasia or achondroplasia fetus. This system will be helpful in the differential diagnosis of thanatophoric dysplasia and achondroplasia in early gestation and in couples concerned about the recurrence of thanatophoric dysplasia due to germinal mosaicism.
© 2018 Japanese Teratology Society.

Entities:  

Keywords:  FGFR3; achondroplasia; noninvasive prenatal testing; thanatophoric dysplasia

Mesh:

Substances:

Year:  2018        PMID: 29542187     DOI: 10.1111/cga.12278

Source DB:  PubMed          Journal:  Congenit Anom (Kyoto)        ISSN: 0914-3505            Impact factor:   1.409


  2 in total

Review 1.  Achondroplasia: a comprehensive clinical review.

Authors:  Richard M Pauli
Journal:  Orphanet J Rare Dis       Date:  2019-01-03       Impact factor: 4.123

2.  Development and validation of an expanded targeted sequencing panel for non-invasive prenatal diagnosis of sporadic skeletal dysplasia.

Authors:  Ching-Yuan Wang; Yen-An Tang; I-Wen Lee; Fong-Ming Chang; Chun-Wei Chien; Hsien-An Pan; H Sunny Sun
Journal:  BMC Med Genomics       Date:  2021-11-17       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.